Shares of Omnicell (NASDAQ:OMCL) rose 1.8% in after-market trading after the company reported Q2 results.
Earnings per share decreased 44.78% year over year to $0.37, which beat the estimate of $0.24.
Revenue of $199,621,000 decreased by 8.18% from the same period last year, which beat the estimate of $183,960,000.
Q3 EPS expected between $0.44 and $0.52.
Q3 revenue expected between $204,000,000 and $212,000,000.
Conference Call Details
Date: Jul 28, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/iom96mm2
52-week high: $94.85
Company's 52-week low was at $54.24
Price action over last quarter: Up 1.01%
Omnicell provides automation and business analytics software for healthcare providers. The firm operates in two segments: automation and analytics and medication adherence. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. This segment contributes the majority of revenue. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.